Earlier this year, two new drugs that have been shown in global trials to slow early-stage Alzheimer's disease, donanemab and ...

SaveHealth reports on advancements in dementia medications, highlighting new treatments that modify disease progression and ...

Dementia is a condition that results in progressive memory or thinking problems. It's now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer's ...

New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, ...

Australia's medicines watchdog has approved Alzheimer's drug lecanemab, which has been shown to "significantly" extend ...

A new drug could halt the progression of Alzheimer’s disease. Trials suggest the treatment, called trontinemab, could be the most powerful weapon yet against dementia. Research will now examine ...

Dementia is a major public health challenge. 55 million people live with dementia worldwide. Alzheimer's disease accounts for ...

Controversial1 Alzheimer’s drug lecanemab has overcome another regulatory hurdle, with Australia’s drugs regulator approving the therapy after two rejections.2 The drug, made by Eisai, faces an uphill ...

The Therapeutic Goods Administration approves the drug Lecanemab, which can slow down cognitive decline in the early stages ...

A new drug to treat early Alzheimer’s has been given the green light for use in Australia, in a significant boost in the fight against the disease.